posted
Medistem Files U.S. Patent Application for Innovative Stem Cell Technology to Treat Lower Back Disorders; Stem Cell Company's Discovery Could Provide Breakthrough for Patients with Lumbar-Related Ailments by Preventing Disc Degeneration Business Wire - May 23, 2006 16:01
SCOTTSDALE, Ariz., May 23, 2006 (BUSINESS WIRE) -- Medistem Laboratories, Inc. (OTCBB:MDSM)(FWB:S2U), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, announced today its filing of a U.S. patent application for an innovative cellular technology to treat lower back ailments by addressing causal issues and developing methodologies to prevent disc degeneration.
Back pain costs the U.S. economy over $50 billion annually and represents the second most common reason for visits to a doctor. It is estimated that 10% of 50-year-old discs and 60% of 70-year-old discs are severely degenerated. The patent application represents a potential therapeutic breakthrough for patients worldwide who suffer from chronic lumbar pain and related lower back disorders caused by disc degeneration. The novel technology is designed to address these problems through the application of regenerative stem cell-based medicine. The proprietary technology increases the potential market value of Medistem's Intellectual Property portfolio.
"The future success of Medistem lies in the commercialization of the best, most innovative and far-reaching stem cell technologies being developed in the world of science," said Neil Riordan, Ph.D., Chairman, and CEO of Medistem. "This latest patent filing is a significant achievement and we're excited by the potential market opportunities and added corporate value presented by our expanding portfolio of intellectual property."
The Medistem discovery relates to the administration of one or more cell types to stimulate lumbar angiogenesis, decrease inflammation, and stimulate regeneration. Significantly, the concept of therapeutic angiogenesis has been investigated for treatments of heart disease, peripheral arterial disease, and other ischemia-related pathologies but only Medistem's technology teaches its groundbreaking potential use for the treatment of lower back ailments associated with disc degeneration. In addition, while a variety of medical approaches exists today to treat lower back problems and associated pain, none actually prevents the process of disc degeneration.
"Common early intervention methods such as exercise, anti-inflammatories and analgesics do not influence the root cause of these problems, while other more serious interventions including spinal fusion, surgery, and artificial disc implants too often present adverse effects, invasiveness and limited full recovery," Riordan added. "We believe we are on our way to developing a major market alternative and superior regenerative solution that would provide safe, effective relief for people worldwide suffering from lumbar-related ailments."
About Medistem Laboratories, Inc.
Medistem Laboratories is an innovative biotechnology company committed to the creation and commercialization of advanced medical therapies based on non-controversial adult stem cells. Medistem's corporate mission is to transform these stem cells into valuable medical treatments. The Company intends to create these treatments from adult stem cells derived from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, but not the controversial embryonic or fetal stem cells that are the focus of ethical and moral debates in some communities. The Company's business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help millions of patients. Initial development and treatment focus will use proprietary technology and cells sourced from umbilical cords, fat, bone marrow, and muscle for advanced treatment of cerebral palsy, stroke, cardiovascular disease and orthopedic diseases, primarily for the international marketplace. Additional applications ultimately will be targeted to the treatment of neurological disorders such as Parkinson's, Alzheimer's and certain types of cancer. Medistem believes it may hold a substantial competitive edge in the worldwide emerging market for stem cell-sourced medical solutions, positioning it to become a leading global provider of stem cell treatments on a fee-for-service basis, while accumulating intellectual property based on clinical and laboratory findings. For more information, please visit http://www.trilogy-capital.com/tcp/medistem/. To read or download Medistem's Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/medistem/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/medistem/quote.html. Medistem is traded on the Frankfurt, Germany, stock exchange under the symbol S2U.
Cautionary Statement
This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements contained herein can be identified by the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," or "anticipates," or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. We wish to caution the reader that these forward-looking statements that are not historical facts, are only predictions. No assurances can be given that the future results indicated, whether expressed or implied, will be achieved.
SOURCE: Medistem Laboratories, Inc.
Medistem Laboratories, Inc. Neil Riordan, Ph.D., 954-727-3662 riordan*medisteminc.com
** Not suggesting to buy or not to buy. Looks interesting.
Readers are cautioned on reading 10Q filings for companies of this type; drugs, medicine, research. Almost always, a 10Q will report tremendous losses which are expected. Companies in this sector rarely generate revenue. These are companies involved in research which depend on funding from the government, universities, private placements and such.
What to look for is how many "donations" and size of those donations along with frequency. Companies involved in good research will display a number of funders and regular funding.
Another item to look for is clinical phase trials. Usually "phase III" trials place a company close to strong upswings in share price when phase III trials are completed and successful.
FDA approval of a medicine, treatment, device or other, almost always causes a skyrocket.
A patent will boost share price, but mildly.
Some cautions.
Companies which produce a "cure" requiring only a nasal inhaler and no FDA approval, SCAM!
Shutting down of clinical trials by the FDA is always a death warrant for a company.
Usually best to not hold a stock too long after an upswing based on good news. Most often, prices begin a downturn and settle at a new bottom price. This can happen somewhat quickly.
Common sense tells you a new "cure" or whatever, must be "something" which is logical, works and addresses very common ailments. Medical devices, usually not a favorable investment. Medicines or "in body" devices, often are a good investment.
"Licensing rights" are the money makers for this sector.
posted
Pharma's are notorious to sell off into news..
Charting is fine and dandy, but no way can it tell you what people will do tomorrow with this Market behaving volitile at best, it's making Dead Cat bounces..This is a dangerous Market, be careful.
Posts: 10729 | From: oregon | Registered: Feb 2005
| IP: Logged |
posted
My opinion is this is strictly a one day technical play.
My thoughts are a majority, if not all, upward swing was realized yesterday. MDSM closed at the high of the day and a majority of trades were "well below" this high suggesting most traders, yesterday, estimate a value less than yesterday's high closing.
A sixty-two percent gain in a day is extreme, especially for patent news, a type of news which usually does not cause such a gain.
Tough to gauge. Just prior to this patent news MDSM displays very strong, high volume downward trading; prices falling hard. This down volume is much stronger than the news upward volume.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
